Direkt zum Inhalt
Merck

I2411

Sigma-Aldrich

Isocitrate Dehydrogenase 1 (NADP+) human

recombinant, expressed in Sf9 cells, ≥90% (SDS-PAGE)

Synonym(e):

IDH1, Isocitrate Dehydrogenase Cytoplasmic

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

CAS-Nummer:
EC-Nummer:
UNSPSC-Code:
12352204
NACRES:
NA.54

Rekombinant

expressed in Sf9 cells

Assay

≥90% (SDS-PAGE)

Form

buffered aqueous glycerol solution

Mol-Gew.

47.6 kDa

Konzentration

≥0.30 mg/mL protein (Bradford)

NCBI-Hinterlegungsnummer

Relevante Krankheit(en)

cancer (lung)

Versandbedingung

dry ice

Lagertemp.

−70°C

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

Human Isocitrate Dehydrogenase (IDH1), also known as oxalosuccinate decarboxylase, full length [amino acids 1-414 (end)] with C-terminal FLAG-tag, expressed in Sf9 cells via a baculovirus expression system.

Anwendung

Human Isocitrate Dehydrogenase (IDH1) is useful for the study of enzyme kinetics, screening inhibitors, and selectivity profiling. It may be useful as a biomarker for diagnosis and prognosis prediction of non-small cell lung cancer .

Biochem./physiol. Wirkung

Human Isocitrate Dehydrogenase (IDH1), also known as oxalosuccinate decarboxylase, is a full length amino acid with a C-terminal FLAG-tag and is expressed in Sf9 cells via a baculovirus expression system. IDH1 expression has been correlated with poor survival of non-small cell lung cancer. IDH1 promotes tumor growth .

Physikalische Form

Solution in 45 mM Tris-HCl, 124 mM NaCl, 2.4 mM KCl, 90 μg/ml FLAG peptide, 3 mM DTT, and 10% glycerol at pH 8.0.

Anwendung

Lagerklassenschlüssel

10 - Combustible liquids

WGK

WGK 1

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable


Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Peter Paschka et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28(22), 3636-3643 (2010-06-23)
To analyze the frequency and prognostic impact of isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) mutations in acute myeloid leukemia (AML). We studied 805 adults (age range, 16 to 60 years) with AML enrolled on German-Austrian AML Study
Fengwei Tan et al.
Molecular & cellular proteomics : MCP, 11(2), M111-M111 (2011-11-09)
Lung cancer is the leading cause of cancer-related death in the world. To explore tumor biomarkers for clinical application, two-dimensional fluorescence difference gel electrophoresis and subsequent MALDI-TOF/TOF mass spectrometry were performed to identify proteins differentially expressed in 12 pairs of
Lenny Dang et al.
Trends in molecular medicine, 16(9), 387-397 (2010-08-10)
The systematic sequencing of glioblastoma multiforme (GBM) genomes has identified the recurrent mutation of IDH1, a gene encoding NADP(+)-dependent isocitrate dehydrogenase 1 (IDH1) that catalyzes the oxidative decarboxylation of isocitrate yielding alpha-ketoglutarate (alpha-KG). Subsequent studies have confirmed recurrent IDH1 and
Yuejun Fu et al.
Biochemical and biophysical research communications, 397(2), 127-130 (2010-06-01)
Heterozygous mutations in either the R132 residue of isocitrate dehydrogenase I (IDH1) or the R172 residue of IDH2 in human gliomas were recently highlighted. Heterozygous mutations in the IDH1 occur in the majority of grade II and grade III gliomas
Yui Mano et al.
Journal of neurosurgery. Pediatrics, 11(5), 518-525 (2013-02-26)
Dysembryoplastic neuroepithelial tumors (DNETs) have conventionally been regarded as benign and stable tumors and considered curable with surgery without adjunctive therapy. Recently, recurrent DNETs with or without malignant transformation have been described. The authors report 2 unusual cases of DNET:

Protokolle

We describe here a rapid and sensitive method to separate and measure D-2-OHG and L-2-OHG enantiomers using high-resolution mass spectrometry (HRMS) detection.

Chromatograms

application for HPLC

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.